Orogenital transmission is often suspected but rarely proven (1) . In our study, use of whole-genome sequencing strongly supported the hypothesis that the oropharyngeal carriage of N. meningitidis by the man who performed oral sex was the source of the urethritis. Moreover, whole-genome sequencing showed that the strains belonged to the ST11 clonal complex. Several studies reported nongonococcal urethritis caused by N. meningitidis ST11 in Japan and the United States (1, 6, 7) . These worldwide descriptions suggest that N. meningitidis S11 might represent an emerging urethrotropic clade.
This case is notable because the patient had highly symptomatic urethritis without risky sexual behavior. In fact, he reported that he and his only sexual partner had not had sex with others before they met.
Since 2010, several clusters of serogroup C invasive meningococcal disease have been reported among men who have sex with men, and sexual transmission is suspected to be involved (8) (9) (10) . These infections led to an extension of the meningococcal vaccine recommendations to men who have sex with men who are engaged in risky behavior in some outbreaks areas. Our case highlights that sexual transmission of N. meningitidis should be considered for all men.
Finally, although systematically collected information is limited, meningococcal urogenital infections are potentially increasing and raising public health concerns. These infections need to be monitored, and bacteriological culture of purulent exudate should always be considered when available. Also, because fidelity might be contested between partners when a sexually transmitted disease is being diagnosed, identification of meningococcal urethritis and its transmission might have a strong psychological effect on the couple. Since 2012, we have used a commercial agar-based screening system (VIPcheck, http://www.vipcheck.nl) containing 2 mg/L of voriconazole (3, 4) . We performed EUCAST susceptibility testing (http://www.eucast.org) and sequencing of the cyp51A gene and promoter on isolates that grew on azole-containing wells (2) .
We calculated the resistance frequency of azole-resistant A. fumigatus isolates for each year, using the number of cultured isolates as denominator. Furthermore, we calculated the patient-adjusted proportion of resistance for each year and for each 5-year period, using the number of patients with a resistant isolate as numerator and of culture-positive patients as denominator. We determined by χ 2 test whether trends of resistance frequency were statistically significant (p<0.05). When 2 different resistance mechanisms were recovered from a single patient, we counted the patient once for determining the resistance proportion but used both isolates to determine the resistance frequency.
Over the 23-year period, 4,268 A. fumigatus isolates were cultured from 2,051 patients, a resistance frequency of 4.2% (179/4,268 isolates). Azole-resistant A. fumigatus was found in 109/2,051 (5.3%) culture-positive patients (Figure, panel A) . The patient-adjusted resistance proportion increased from 0% in 1997 to 9.5% in 2016 (Figure,  panel B) . The increase of resistance was not statistically significant when the proportion of resistance for each consecutive year was analyzed. However, the 5-year proportion of resistance increased from 0. (Figure, panel B) .
TR 34 /L98H was the most prevalent resistance mutation over the 23-year period; it was present in 77/109 (70.6%) patients with drug-resistant A. fumigatus (Figure, panel C) . We observed an increasing trend in azole resistance prevalence in clinical A. fumigatus isolates until 2011, using number of patients with a positive culture as denominator. After 2011, the 5-year proportion of resistance remained stable. The advantages and disadvantages of different approaches of reporting resistance frequency remain under debate (5) . Experts have recommended 10% resistance rate as the threshold for reconsideration of primary antifungal therapy (6), which indicates a need for consensus in how to determine resistance rates (5).
Although we found a substantial increase in azole resistance frequency over time, our study showed variation between consecutive years. Therefore, analysis of culture-positive patients over multiple years is required to determine local resistance epidemiology. Furthermore, resistance rates calculated using Aspergillus disease as denominator provide more information to support changes in empiric treatment decisions, but the low number of culturepositive patients in risk groups makes it difficult to obtain accurate estimates.
Various factors might have caused bias over the long period. The method of resistance detection changed from an agar-slant containing itraconazole to a system that contained 3 azoles. Voriconazole-or posaconazole-resistant isolates with low itraconazole MICs may have been initially missed, but this phenotype is very uncommon (7) . Other factors include increased awareness of resistance, the policy to screen multiple A. fumigatus colonies after observation of patients with mixed azole-susceptible and azole-resistant infection (8) , and local changes in aspergillus disease risk groups.
Resistance was dominated by environmental resistance mutations TR 34 /L98H and TR 46 /Y121F/T289A, although the number of patients with TR 46 /Y121F/T289A decreased in recent years. Furthermore, in the last 5 years, ≈15% of resistant isolates harbored a wild-type Cyp51A gene, suggesting that other resistance mechanisms may be emerging. Because commercial PCR tests detect only resistance mechanisms with TR 34 (9) or TR 34 and TR 46 (10), our observation is relevant for using these assays in culturenegative patients.
In summary, our study indicates an increasing azole resistance trend in clinical A. fumigatus isolates in the Netherlands. Furthermore, our results highlight difficulties encountered in establishing local epidemiology of this resistance.
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